New generation vectored vaccines

In R&D by Freya SmaleLeave a Comment

jenner institute

Pushing innovation beyond the antigen to meet the health needs of resource-poor settings

Dr Migena Bregu, Project Manager, Jenner Institute, University of Oxford joined us the World Vaccine Congress Lyon 2012 to lead the discussion into new generation vectored vaccines and pushing innovation beyond the antigen to meet the health need of resource. New Generation Vectored Vaccines could make a difference in the fight against Malaria, TB and HIV. The Jenner Institute's project has two main goals:

Genetic Adjuvants: to improve the immunogenicity of the Antigen
Thermostable Vaccine Formulations: to make vaccine deployment free of the cold-chain

Three types of adjuvant are being investigated: Signalling, Structural and Cellular Trafficking.

Why not download the full presentation and discover more about new generation vectored vaccines – Pushing innovation beyond the antigen to meet the health needs of resource-poor settings

· Genetic adjuvants: (i) pro-inflammatory activators (ii) multimerisation of the antigen (iii) modulators of antigen processing

· Thermostable formulations for vaccines

· How to translate clinical efficacy to field effectiveness

Download the full presentation here >

For more information about this and other topics discussed at the World Vaccine Congress Lyon, subscribe to the Vaccine Nation newsletter, or visit the event website.

For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *